Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
Copyright © 2016 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissionsoup.com..
BACKGROUND: Therapeutic monoclonal anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies are associated with immune-mediated enterocolitis. The aim of this study was to provide a detailed description of this entity.
METHODS: We included patients with endoscopic signs of inflammation after anti-CTLA-4 infusions for cancer treatment. Other causes of enterocolitis were excluded. Clinical, biological and endoscopic data were recorded. A single pathologist reviewed endoscopic biopsies and colectomy specimens from 27 patients. Patients with and without enterocolitis after ipilimumab-treated melanoma were compared, to identify clinical factors associated with enterocolitis.
RESULTS: Thirty-nine patients with anti-CTLA-4 enterocolitis were included (ipilimumab n = 37; tremelimumab n = 2). The most frequent symptom was diarrhoea. Ten patients had extra-intestinal manifestations. Most colonoscopies showed ulcerations involving the rectum and sigmoid, 66% of patients had extensive colitis, 55% had patchy distribution and 20% had ileal inflammation. Endoscopic colonic biopsies showed acute colitis in most patients, while half of the patients had chronic duodenitis. Thirty-five patients received steroids that led to complete clinical remission in 13 patients (37%). Twelve patients required infliximab, of whom 10 (83%) responded. Six patients underwent colectomy (perforation n = 5; toxic megacolon n = 1); one of them died postoperatively. Four patients had a persistent enterocolitis at follow-up colonoscopy. Patients with enterocolitis were more frequently prescribed NSAIDs compared with patients without enterocolitis (31 vs 5%, p = 0.003).
CONCLUSIONS: Ipilimumab and tremelimumab may induce a severe and extensive form of inflammatory bowel disease. Rapid escalation to infliximab should be advocated in patients who do not respond to steroids. Patients treated with anti-CTLA-4 should be advised to avoid NSAIDs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Journal of Crohn's & colitis - 10(2016), 4 vom: 15. Apr., Seite 395-401 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Marthey, L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-CTLA-4 |
|---|
| Anmerkungen: |
Date Completed 30.12.2016 Date Revised 10.12.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1093/ecco-jcc/jjv227 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM256597871 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM256597871 | ||
| 003 | DE-627 | ||
| 005 | 20231224181009.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ecco-jcc/jjv227 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0855.xml |
| 035 | |a (DE-627)NLM256597871 | ||
| 035 | |a (NLM)26783344 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Marthey, L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.12.2016 | ||
| 500 | |a Date Revised 10.12.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2016 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: Therapeutic monoclonal anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies are associated with immune-mediated enterocolitis. The aim of this study was to provide a detailed description of this entity | ||
| 520 | |a METHODS: We included patients with endoscopic signs of inflammation after anti-CTLA-4 infusions for cancer treatment. Other causes of enterocolitis were excluded. Clinical, biological and endoscopic data were recorded. A single pathologist reviewed endoscopic biopsies and colectomy specimens from 27 patients. Patients with and without enterocolitis after ipilimumab-treated melanoma were compared, to identify clinical factors associated with enterocolitis | ||
| 520 | |a RESULTS: Thirty-nine patients with anti-CTLA-4 enterocolitis were included (ipilimumab n = 37; tremelimumab n = 2). The most frequent symptom was diarrhoea. Ten patients had extra-intestinal manifestations. Most colonoscopies showed ulcerations involving the rectum and sigmoid, 66% of patients had extensive colitis, 55% had patchy distribution and 20% had ileal inflammation. Endoscopic colonic biopsies showed acute colitis in most patients, while half of the patients had chronic duodenitis. Thirty-five patients received steroids that led to complete clinical remission in 13 patients (37%). Twelve patients required infliximab, of whom 10 (83%) responded. Six patients underwent colectomy (perforation n = 5; toxic megacolon n = 1); one of them died postoperatively. Four patients had a persistent enterocolitis at follow-up colonoscopy. Patients with enterocolitis were more frequently prescribed NSAIDs compared with patients without enterocolitis (31 vs 5%, p = 0.003) | ||
| 520 | |a CONCLUSIONS: Ipilimumab and tremelimumab may induce a severe and extensive form of inflammatory bowel disease. Rapid escalation to infliximab should be advocated in patients who do not respond to steroids. Patients treated with anti-CTLA-4 should be advised to avoid NSAIDs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-CTLA-4 | |
| 650 | 4 | |a enterocolitis | |
| 650 | 4 | |a ipilimumab | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a CTLA-4 Antigen |2 NLM | |
| 650 | 7 | |a Ipilimumab |2 NLM | |
| 650 | 7 | |a tremelimumab |2 NLM | |
| 650 | 7 | |a QEN1X95CIX |2 NLM | |
| 700 | 1 | |a Mateus, C |e verfasserin |4 aut | |
| 700 | 1 | |a Mussini, C |e verfasserin |4 aut | |
| 700 | 1 | |a Nachury, M |e verfasserin |4 aut | |
| 700 | 1 | |a Nancey, S |e verfasserin |4 aut | |
| 700 | 1 | |a Grange, F |e verfasserin |4 aut | |
| 700 | 1 | |a Zallot, C |e verfasserin |4 aut | |
| 700 | 1 | |a Peyrin-Biroulet, L |e verfasserin |4 aut | |
| 700 | 1 | |a Rahier, J F |e verfasserin |4 aut | |
| 700 | 1 | |a Bourdier de Beauregard, M |e verfasserin |4 aut | |
| 700 | 1 | |a Mortier, L |e verfasserin |4 aut | |
| 700 | 1 | |a Coutzac, C |e verfasserin |4 aut | |
| 700 | 1 | |a Soularue, E |e verfasserin |4 aut | |
| 700 | 1 | |a Lanoy, E |e verfasserin |4 aut | |
| 700 | 1 | |a Kapel, N |e verfasserin |4 aut | |
| 700 | 1 | |a Planchard, D |e verfasserin |4 aut | |
| 700 | 1 | |a Chaput, N |e verfasserin |4 aut | |
| 700 | 1 | |a Robert, C |e verfasserin |4 aut | |
| 700 | 1 | |a Carbonnel, F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Crohn's & colitis |d 2007 |g 10(2016), 4 vom: 15. Apr., Seite 395-401 |w (DE-627)NLM204021901 |x 1876-4479 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2016 |g number:4 |g day:15 |g month:04 |g pages:395-401 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ecco-jcc/jjv227 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2016 |e 4 |b 15 |c 04 |h 395-401 | ||